OncoMatch/Clinical Trials/NCT06185556
COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
Is NCT06185556 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies non-drug interventions for colorectal cancer.
The primary objective of this phase IIb/III, prospective, randomized clinical trial is to compare the efficacy of irreversible electroporation (IRE) with stereotactic body radiotherapy (SBRT) in patients with perivascular or peribiliary colorectal liver metastases (CRLM), that are not amenable for surgical resection or thermal ablation. Efficacy is assessed in terms of local control at 2 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ASA 0–3
Lab requirements
Blood counts
adequate bone marrow function as assessed by laboratory requirements within 7 days prior to inclusion
Kidney function
adequate renal function as assessed by laboratory requirements within 7 days prior to inclusion
Liver function
adequate liver function as assessed by laboratory requirements within 7 days prior to inclusion; compromised liver function (e.g. signs of portal hypertension, INR > 1.5 without use of anticoagulants, ascites) [excluded]
Adequate bone marrow, liver and renal function as assessed by laboratory requirements to be conducted within 7 days prior to definite inclusion; Compromised liver function (e.g. signs of portal hypertension, INR > 1.5 without use of anticoagulants, ascites) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify